Temporal trends and socioeconomic determinants of cytoreductive nephrectomy (CN) utilization for metastatic renal cell carcinoma (mRCC) in the United States (US).

被引：0
|
作者：
Esagian, Stepan M.
Msaouel, Pavlos
Karam, Jose A.
Gartrell, Benjamin
Makrakis, Dimitrios
机构：
[1] Albert Einstein Coll Med, NYC Hlth Hosp Jacobi, Dept Med, Bronx, NY USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[4] Montefiore Einstein Canc Ctr, Bronx, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.447
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma
    不详
    JOURNAL OF ENDOUROLOGY, 2005, 19 : A39 - A39
  • [32] Impact of cytoreductive nephrectomy (CN) on survival in metastatic renal cell cancer (mRCC) treated with immune checkpoint inhibitors (ICI).
    Perimbeti, Stuthi
    Jiang, Changchuan
    Deng, Lei
    Roy, Arya
    Gopalakrishnan, Keerthy
    Chatta, Gurkamal S.
    George, Saby
    Gopalakrishnan, Dharmesh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [33] Partial cytoreductive nephrectomy versus cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Vitruk, Iurly
    Stakhovskyi, Oleksandr
    Voylenko, Oleg
    Kotov, Volodymyr
    Pikul, Maxim
    Stakhovsky, Eduard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Lapaloscopic cytoreductive nephrectomy for metastatic renal cell carcinoma
    Fujita, T.
    Hattori, R.
    Kinukawa, T.
    Ono, Y.
    JOURNAL OF ENDOUROLOGY, 2006, 20 : A231 - A231
  • [35] Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma PRO
    Wood, Christopher G.
    JOURNAL OF UROLOGY, 2013, 190 (02) : 387 - 388
  • [36] Long-term survival of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN)
    Richey, S. L.
    Culp, S. H.
    Jonasch, E.
    Corn, P. G.
    Pagliaro, L. C.
    Tamboli, P.
    Patel, K.
    Matin, S. F.
    Tannir, N. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [37] Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME)
    Bex, A.
    Mulders, P.
    Jewett, M. A. S.
    Wagstaff, J.
    van Velthoven, R.
    Pes, P. M. Laguna
    Wood, L.
    van Melick, H. H. E.
    Soetekouw, P.
    Lattouf, J. B.
    Powles, T.
    Boleti, E.
    de Jong, I-J.
    Rottey, S.
    Tombal, B.
    Marreaud, S.
    Collette, L.
    Collette, S.
    Blank, C. U.
    Haanen, J. B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [38] The role of cytoreductive nephrectomy (CN) for patients with metastatic renal cell carcinoma (mRCC) in the setting of retroperitoneal lymphadenopathy: An analysis of the National Cancer Database (NCDB)
    Reddy, Akshay
    Sparks, Andrew D.
    Whalen, Michael Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [39] PARTIAL NEPHRECTOMY (PN) VERSUS RADICAL NEPHRECTOMY (RN) FOR NON-METASTATIC RENAL CELL CARCINOMA (RCC): UTILIZATION TRENDS IN THE UNITED STATES
    Sun, M.
    Abdollah, F.
    Jeldres, C.
    Schmitges, J.
    Djahangirian, O.
    Liberman, D.
    Ismail, S.
    Tian, Z.
    Shariat, S. F.
    Karakiewicz, P., I
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 200 - 200
  • [40] The Impact of Targeted Therapy on Management of Metastatic Renal Cell Carcinoma: Trends in Systemic Therapy and Cytoreductive Nephrectomy Utilization COMMENT
    Kuebler, Hubert R.
    UROLOGY, 2015, 85 (02) : 450 - 451
12345